Drugs / ZELATRIAZIN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02959892 | Dec 2016 → May 2017 | — | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02748694 | May 2016 → Sep 2019 | schizophrenia | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03319953 | Dec 2017 → Sep 2019 | schizophrenia | Neurocrine Biosciences | Completed | Missed primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZELATRIAZIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4779773 ↗ |
| Known as | NBI-1065846 | “TAK-041 (NBI-1065846), an orally available, investigational, small molecule agonist of GPR139, an orphan G-protein-coupled receptor, has shown promise in preclinical studies...” PMID 35277995 ↗ Apr 20221“TAK-041 (also known as NBI-1065846) is a selective and potent small-molecule agonist of GPR139, an orphan G-protein-coupled receptor” PMID 40817174 ↗ Aug 2025 |
| Known as | TAK -041 | “The drug being tested in this study is called TAK-041.” NCT02959892 ↗ |
| Known as | Zelatriazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4779773 ↗ |
| Known as | Zelatriazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4779773 ↗ |
| Action | Activate | “TAK-041 (NBI-1065846), an orally available, investigational, small molecule agonist of GPR139, an orphan G-protein-coupled receptor” PMID 35277995 ↗ Apr 2022 |
| Modality | Small molecule | “TAK-041 (NBI-1065846), an orally available, investigational, small molecule agonist of GPR139, an orphan G-protein-coupled receptor” PMID 35277995 ↗ Apr 2022 |
| Route | Oral | “TAK-041 40 mg, tablet, orally, once on Day 1 in fasted state (Regimen A) in Cohort 1.” NCT02748694 ↗ |
| Target | GPR139 | “TAK-041 (NBI-1065846), an orally available, investigational, small molecule agonist of GPR139, an orphan G-protein-coupled receptor” PMID 35277995 ↗ Apr 2022 |